Comparison of the effects of carvedilol and metoprolol on myocardial infarction and cardiac function in hemodialysis patients

doi:10.19803/j.1672-8629.20210660

Abstract

Abstract: Objective To compare the effects of carvedilol and metoprolol on myocardial infarction and cardiac function in hemodialysis patients, so as to provide reference for clinical medications. Methods A total of 180 patients receiving maintenance hemodialysis in our hospital between December 10, 2019 and December 31, 2020 were selected, who were randomly divided into the carvedilol group (n=60), metoprolol group (n=60) and control group (n=60). The carvedilol group received maintenance hemodialysis + carvedilol (oral), the metoprolol group was given maintainenance hemodialysis + metoprolol succinate sustained-release tablets (oral), and the control group underwent twelve months of maintenance hemodialysis only. The incidence of acute myocardial infarction was compared between the three groups, while the differences in amino-terminal brain natropeptide precursor (NT-proBNP), high-sensitive cardiac troponin T (hs-cTNT), myoglobin (Mb) and serum creatine kinase isoenzyme (CK-MB) and LVEF among the three groups were recorded. Results It was found that the incidence of acute myocardial infarction was significantly lower in the carvecilol group and metoprolol group than in the control group (P<0.05). The levels of NT-proBNP were significantly lower in the control group, but the LVEF value was significantly higher than in the control group, and the difference was statistically significant (P<0.05). The levels of hs-cTNT, Mb and CK-MB were not significantly different from those of the control group (P>0.05). Compared with the metoprolol group, the incidence of acute myocardial infarction in the carvedilol group was slightly lower, but the difference was not statistically significant (P>0.05). There was no significant difference in NT-proBNP, hs-cTNT, Mb, CK-MB and LVEF values between the metoprolol group and the carvedilol group. Conclusion Both carvedilol and metoprolol can reduce the incidence of acute myocardial infarction and improve cardiac function in maintenance hemodialysis patients, but there is no significant difference between the two groups.

Key words: carvedilol, metoprolol, acute myocardial infarction, maintenance hemodialysis

CLC Number:

R972

FAN Leilei, YANG Jing, XIAO Qianqian, GAO Dongxue, QU Suping. Comparison of the effects of carvedilol and metoprolol on myocardial infarction and cardiac function in hemodialysis patients[J]. Chinese Journal of Pharmacovigilance, 2022, 19(12): 1338-1343.

References

[1] SHAFI T, POWE NR, MEYER TW, et al.Trimethylamine N-Oxide and cardiovascular events in hemodialysis patients[J]. J Am Soc Nephrol, 2017, 28(1): 321-331.
[2] SARAN R, ROBINSON B, ABBOTT KC, et al.US renal data system 2016 annual data report: epidemiology of kidney disease in the United States[J]. Am J Kidney Dis, 2017, 69(3): A7-A8.
[3] Chinese Society of Nephrology Expert Cooperation Group of Chronic Kidney Disease Hypertension Treatment. Practice guidelines for α/β blockers in the treatment of hypertension in chronic kidney disease[J]. Chinese Medical Journal(中华医学杂志) , 2013, 93(48): 3812-3816.
[4] Chinese Expert Consensus Group on Application of β-adrenergic Receptor Blockers in Standardized Treatment of Coronary Heart Disease. Chinese expert consensus on the standardized treatment of coronary heart disease with β-adrenergic receptor blockers[J]. Chinese Journal of Circulation(中国循环杂志) , 2020, 35(2): 108-123.
[5] KONSTANTINIDIS I, NADKARNI GN, YACOUB R, et al.Representation of patients with kidney disease in trials of cardiovascular interventions: an updated systematic review[J]. JAMA Intern Med, 2016, 176(1): 121-124.
[6] YANG XL, LI JX, HU DS, et al.Predicting the 10-year risks of atherosclerotic cardiovascular disease in chinese population: The China-PAR Project (Prediction for ASCVD Risk in China)[J]. Circulation, 2016, 134(19):1430-1440.
[7] COZZOLINO M, MANGANO M, STUCCHI A, et al. Cardiovascular disease in dialysis patients[J]. Nephrol Dial Transplant, 2018, 33(3): iii28-iii34.
[8] MAYER CC, MATSCHKAL J, SARAFIDIS PA, et al.Association of ambulatory blood pressure with all-cause and cardiovascular mortality in hemodialysis patients: effects of heart failure and atrial fibrillation[J]. J Am Soc Nephrol, 2018, 29(9): 2409-2417.
[9] WU HL.Efficacy analysis of metoprolol and carvedilol in the treatment of chronic heart failure[J]. Medical Innovation in China(中国医学创新) ,2018, 32(15): 43-46.
[10] WANG ZH.Comparison of short-term and long-term efficacy of two β -blockers in the treatment of chronic heart failure[J]. Journal of Clinical Rational Drug Use(临床合理用药杂志) , 2016, 9(16): 58-61.
[11] TIEU A, VELENOSI TJ, KUCEY AS, et al.β-blocker dialyzability in maintenance hemodialysis patients: a randomized clinical trial[J]. Clin J Am Soc Nephrol, 2018, 13(4): 604-611.
[12] ASSIMON MM, BROOKHART MA, FINE JP, et al.A comparative study of carvedilol versus metoprolol initiation and 1-year mortality among individuals receiving maintenance hemodialysis[J]. Am J Kidney Dis, 2018, 72(3): 337-348.
[13] ZHANG YP, ZHAO LS.Observation on the curative effect of metoprolol in the treatment of severe heart failure[J]. Electronic Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular Disease(中西医结合心血管病电子杂志) , 2020, 8(22): 39-40.
[14] FENG WH.Effect of metoprolol succinate on cardiac function in patients with coronary heart disease and heart failure[J]. Electronic Journal of Integrated Traditional Chinese and Western Medicine Cardiovascular Disease(中西医结合心血管病电子杂志) , 2020, 8(29): 53-197.
[15] HANNA F, LORELLA T, TOBIAS T, et al.Bisoprolol compared with carvedilol and metoprolol succinate in the treatment of patients with chronic heart failure[J]. Clin Res Cardiol, 2017, 106(9): 711-721.
[16] ZHOU H, SIM JJ, SHI JX, et al.β-blocker use and risk of mortality in heart failure patients initiating maintenance dialysis[J]. American Journal of Kidney Diseases, 2020, 3(20): 1001-1009.
[17] MA JC, DU LB, LIANG XL, et al.Effect of carvedilol on cardiac function in patients with diabetic nephropathy undergoing hemodialysis[J]. Journal of Kidney Disease and Kidney Transplantation on Dialysis(肾脏病与透析肾移植杂志) , 2018, 27(2): 147-150.